Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo

Journal of Rheumatology

Volumn 27, Issue 8, 2000, Pages 1876-1883

  Bensen, W G ^a   Zhao, S Z ^a   Burke, T A ^a   Zabinski, R A ^a   Makuch, R W ^a   Maurath, C J ^a   Agrawal, N M ^a   Geis, G S ^a   Bucciarelli, K ^a  

^a PFIZER INC   (United States)

Author keywords

Arthritis; Dyspepsia; Nsaid

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; UPPER GASTROINTESTINAL TRACT;

ABDOMINAL PAIN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DIGESTIVE SYSTEM; DOUBLE-BLIND METHOD; DYSPEPSIA; FEMALE; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NAPROXEN; NAUSEA; OSTEOARTHRITIS; PROSPECTIVE STUDIES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RISK FACTORS; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033843672     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Dyspepsia in NSAID users: The size of the problem
2. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury
3. Epidemiology of NSAID-related gastrointestinal side effects
4. Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy
5. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial
6. NSAID induced gastrointestinal complications: The ARAMIS perspective - 1997. Arthritis, Rheumatism, and Aging Medical Information Sytem
7. Effect of non-steroidal anti-inflammatory drugs on dyspeptic symptoms
8. Dyspepsia: How should we measure it?
9. Dyspepsia and dyspepsia subgroups: A population-based study
10. Management of dyspepsia: Report of a working party
11. Definition and investigation of dyspepsia. Consensus of an international ad hoc working party
12. Economic costs of functional dyspepsia
13. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly
14. Prescribing patterns for dyspepsia in primary care: A prospective study of selected general practitioners
15. Nonsteroidal antiinflammatory drugs - Differences and similarities
16. A two-year, placebo-controlled trail of non-steroidal anti-inflammatory therapy in osteoarthritis of the knee joint
17. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis
18. Four commonly prescribed non-steroidal anti-inflammatory drugs for rheumatoid arthritis
19. Patterns of interchange in the dispensing of non-steroidal anti-inflammatory drugs
20. An equilibrium model of drug utilization
21. Patient non-compliance: Deviance or reasoned decision-making?
22. Nonsteroidal therapy of rheumatoid arthritis and osteoarthritis: How physicians manage treatment failures
23. Gastrointestinal tract complications of nonsteroidal anti- inflammatory drug treatment in rheumatoid arthritis
24. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4- methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib)
25. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic
26. Celecoxib is associated with a significantly lower incidence of clinically significant upper gastrointestinal events in osteoarthritis and rheumatoid arthritis patients as compared to NSAIDs
27. The anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trail
28. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
29. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association
30. Premarketing studies in the drug approval process: Understanding their limitations regarding the assessment of drug safety
31. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users
32. Prevention of peptic ulcers and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy: A Nordic multicentre study
33. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflamatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Grroup
34. Prevention of gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs: Controlled trial of ranitidine
35. Effect of cimetidine on gastrointestinal symptoms in patients taking nonsteroidal antiinflammatory drugs
36. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs
37. Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs
38. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration
39. Recent considerations in non-steroidal anti-inflammatory drug gastropathy
40. A 6-month, double-blind study comparing nabumetone to naproxen in the treatment of osteoarthritis
41. The Norwegian multicenter study
42. Efficacy and tolerability of enteric-coated naproxen in the treatment of osteoarthritis and rheumatoid arthritis: A double-blind comparison with standard naproxen followed by an open-label trial
43. A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis
44. Double-blind study of naproxen in osteoarthritis of the knee joint
45. Comparison of timegadine and naproxen in rheumatoid arthritis. A placebo controlled trial
46. From experiment to experience: Side effects of nonsteroidal anti-inflammatory drugs